Back

Catheter ablation versus medical therapy for treatment of symptomatic frequent ventricular premature complexes as a first-line therapy in pediatric population: One-year follow up of a randomized study

17 March 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Best graded abstracts Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2019

About the speaker

Photo
Doctor Alexander Romanov

E. Meshalkin National Medical Research Center of the Ministry of Health, Novosibirsk (Russian Federation)

5 More presentations in this session

Presentation thumbnail
Phrenic nerve injury during pulmonary vein isolation using the second-generation cryoballoon: first results of the worldwide YETI registry
Doctor C. Heeger (Hamburg, DE)
Abstract Slides Video
Presentation thumbnail
Pulmonary vein isolation by high-power short-duration radiofrequency applications: short term efficacy and safety in patients with atrial fibrillation
Doctor C. Escobar Cervantes (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Novel ultra-low temperature cryoablation system: safety, efficacy and long-term durability
Slides Video
Presentation thumbnail
Association between QRS shortening and mortality after implantation of cardiac resynchronization therapy: results from the DANISH study
Doctor C. Lund-Andersen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Haemodynamically compromising ventricular tachycardia assessed under haemodynamic support depends on functional conduction properties of borderzone tissue
Doctor J. Whitaker (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Best graded abstracts

The Event

Event poster

EHRA 2019

17 March - 19 March 2019
You may be interested in
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?
thumbnail
Congress Presentation
Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy in post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources